{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:40:02Z","timestamp":1783554002509,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["T-A-003"],"award-info":[{"award-number":["T-A-003"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018538","name":"National Ten Thousand Talent Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111642","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T08:06:37Z","timestamp":1707206797000},"page":"111642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer"],"prefix":"10.1016","volume":"129","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111642_b0005","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2024.111642_b0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0015","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2024.111642_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.111642_b0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2024.111642_b0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111642_b0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.26094","article-title":"VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2","volume":"130","author":"Ziogas","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111642_b0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4049\/jimmunol.0900397","article-title":"Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production","volume":"184","author":"Basu","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.111642_b0050","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.111642_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cca.2018.06.032","article-title":"Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells","volume":"485","author":"Qiu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.intimp.2024.111642_b0060","article-title":"Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111642_b0065","article-title":"Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.111642_b0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.111642_b0075","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.111642_b0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and Gemox is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.111642_b0085","first-page":"3455","article-title":"Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study","volume":"12","author":"Zhang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2024.111642_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000324704","article-title":"Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?","volume":"80","author":"Kemeny","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.intimp.2024.111642_b0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0b013e3181d2709a","article-title":"Phase I\/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301)","volume":"34","author":"Inaba","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/1751-2980.13127","article-title":"Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma","volume":"23","author":"Zhang","year":"2022","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.intimp.2024.111642_b0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.intimp.2024.111642_b0125","unstructured":"National Cancer Institute. National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, 2017. 27 Nov 2017 [Cited 9 January, 2024]. <https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf>."},{"key":"10.1016\/j.intimp.2024.111642_b0130","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s00262-023-03466-8","article-title":"Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study","volume":"72","author":"Zhu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2024.111642_b0135","doi-asserted-by":"crossref","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111642_b0140","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111642_b0145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0150","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0155","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0160","doi-asserted-by":"crossref","unstructured":"Villanueva L, Lwin Z, Chung HCC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. J Clin Oncol. 39(2021)3_suppl,321.","DOI":"10.1200\/JCO.2021.39.3_suppl.321"},{"key":"10.1016\/j.intimp.2024.111642_b0165","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobil. Surg Nutr."},{"key":"10.1016\/j.intimp.2024.111642_b0170","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2021.39.15_suppl.4094","article-title":"Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"39","author":"Jian","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0175","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/j.annonc.2022.07.093","article-title":"A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers","volume":"33","author":"Li","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111642_b0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111642_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111642_b0190","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer."},{"key":"10.1016\/j.intimp.2024.111642_b0195","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:42:18Z","timestamp":1769229738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"alternative-id":["S1567576924001607"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111642","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111642"}}